Royal Philips announced regulatory clearance in the USA of Elevate Plus, bringing advanced imaging and a suite of AI and automation capabilities to Philips EPIQ Elite and Affiniti,… read more.
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June… read more.
Three-quarters of people who respond well to the newest types of biologics for psoriasis can safely reduce their dosage, often even by half. These medications then work just… read more.
Amneal Pharmaceuticals announced that the FDA has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. The product is eligible for Competitive Generic… read more.
GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery… read more.
Pediatric flu vaccines significantly reduce the number of childhood cases of influenza, new research from Harvard Medical School confirms. The findings, published on June 1 in JAMA Pediatrics, show… read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued nineteen positive recommendations across two days in May 2026, covering a broad spectrum of… read more.
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over… read more.
Cytokinetics, Incorporated announced the first commercial European launch of Myqorzo (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy… read more.
Substantial variations in referrals for advanced heart failure therapies are apparent across the UK and Ireland, with no obvious link to geographical location or social deprivation to explain… read more.
Clinical Pharmacy Congress highlights High cholesterol is a key modifiable risk factor for cardiovascular disease, but many eligible patients are not receiving lipid-lowering therapy. A service evaluation by… read more.
The MHRA confirmed that it granted a UK marketing authorisation to Wayrilz (rilzabrutinib) for adults with immune thrombocytopenia (ITP) whose previous treatments have not worked sufficiently. The approval… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
